The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

• Main Authors: Kristine Griffett (Author), Ryan D. Welch (Author), Colin A. Flaveny (Author), Grant R. Kolar (Author), Brent A. Neuschwander-Tetri (Author), Thomas P. Burris (Author)
• Format: Book
• Published: Elsevier, 2015-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...